|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
JP3041051B2
(ja)
*
|
1995-10-10 |
2000-05-15 |
ファイザー・インコーポレーテッド |
遺伝子治療における神経性炎症の予防のためのｎｋ−１レセプターアンタゴニスト
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
*
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
CA2630062C
(en)
*
|
2000-07-03 |
2014-10-14 |
Bristol-Myers Squibb Company |
Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
MXPA03006699A
(es)
*
|
2001-01-26 |
2004-05-31 |
Univ Emory |
Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
|
|
ATE390931T1
(de)
*
|
2001-05-23 |
2008-04-15 |
Bristol Myers Squibb Co |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
CN1665533A
(zh)
*
|
2002-05-02 |
2005-09-07 |
康涅狄格大学健康中心 |
热激蛋白用于增强抗体疗法功效的用途
|
|
JP2007511507A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ジェンベク、インコーポレイティッド |
癌を処置するための治療レジメン
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
EP2468300B1
(en)
|
2006-09-26 |
2017-12-20 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
CA2703263C
(en)
*
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Immunosuppressive polypeptides and nucleic acids
|
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
EP2621514B1
(en)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
PL2811981T3
(pl)
|
2012-02-07 |
2019-09-30 |
Infectious Disease Research Institute |
Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
|
|
SMT201800368T1
(it)
|
2012-05-16 |
2018-09-13 |
Immune Design Corp |
Vaccini per l'infezione da virus-2 herpes simplex
|
|
CA2909221A1
(en)
|
2013-04-18 |
2014-10-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
RU2761870C2
(ru)
|
2016-05-16 |
2021-12-13 |
Инфекшес Дизис Рисёрч Инститьют |
Состав, содержащий агонист tlr, и способы применения
|
|
EP3463300A1
(en)
|
2016-06-01 |
2019-04-10 |
Infectious Disease Research Institute |
Nanoalum particles containing a sizing agent
|
|
EP3678695A1
(en)
|
2017-09-08 |
2020-07-15 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|